Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA panel has approved broader use of J&J and Bristol Myers' cell therapies for myeloma, while Orchard plans to sell the world's priciest gene therapy. Madrigal has won FDA approval for the first drug for Mash, but faces uncertainty regarding sales potential. Additionally, Bio has changed its stance and is backing a bill to limit China's role in US biotech. Merck reveals plans to develop newer HPV shots, and other news includes trends in obesity drug revolution, state of drug pricing in 2024, and increasing diversity in clinical trials. Stay tuned for more updates in the Pharma and Biotech world.